MX337421B - Sales farmaceuticamente aceptables de 2-{4-[(3s)-piperidin-3-il]fe nil}-2h-indazol-7-carboxamida. - Google Patents
Sales farmaceuticamente aceptables de 2-{4-[(3s)-piperidin-3-il]fe nil}-2h-indazol-7-carboxamida.Info
- Publication number
- MX337421B MX337421B MX2010006593A MX2010006593A MX337421B MX 337421 B MX337421 B MX 337421B MX 2010006593 A MX2010006593 A MX 2010006593A MX 2010006593 A MX2010006593 A MX 2010006593A MX 337421 B MX337421 B MX 337421B
- Authority
- MX
- Mexico
- Prior art keywords
- adp
- poly
- present
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical class N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 title 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000012623 DNA damaging agent Substances 0.000 abstract 1
- 230000033616 DNA repair Effects 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028851 Necrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 206010038997 Retroviral infections Diseases 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 150000001408 amides Chemical group 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000002222 downregulating effect Effects 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- 208000037816 tissue injury Diseases 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1033308P | 2008-01-08 | 2008-01-08 | |
| PCT/GB2009/000041 WO2009087381A1 (en) | 2008-01-08 | 2009-01-08 | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2010006593A MX2010006593A (es) | 2010-12-21 |
| MX337421B true MX337421B (es) | 2016-03-04 |
Family
ID=40404013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010006593A MX337421B (es) | 2008-01-08 | 2009-01-08 | Sales farmaceuticamente aceptables de 2-{4-[(3s)-piperidin-3-il]fe nil}-2h-indazol-7-carboxamida. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8436185B2 (enExample) |
| EP (1) | EP2240466B1 (enExample) |
| JP (1) | JP5989965B2 (enExample) |
| KR (1) | KR101653548B1 (enExample) |
| CN (2) | CN106008460B (enExample) |
| AU (1) | AU2009203598B2 (enExample) |
| BR (1) | BRPI0906020A2 (enExample) |
| CA (1) | CA2711491C (enExample) |
| ES (1) | ES2548131T3 (enExample) |
| FR (1) | FR18C1020I2 (enExample) |
| IL (1) | IL206201A (enExample) |
| MX (1) | MX337421B (enExample) |
| NL (1) | NL300938I2 (enExample) |
| NZ (1) | NZ586675A (enExample) |
| WO (1) | WO2009087381A1 (enExample) |
| ZA (1) | ZA201003902B (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2740746A1 (en) | 2008-10-14 | 2010-04-22 | Ning Xi | Compounds comprising a spiro-ring and and methods of use |
| EP2408300B1 (en) | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| DK3150610T3 (da) | 2010-02-12 | 2019-11-04 | Pfizer | Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on |
| US9580407B2 (en) | 2012-12-07 | 2017-02-28 | Merck Sharp & Dohme Corp. | Regioselective N-2 arylation of indazoles |
| PL3157566T3 (pl) | 2014-06-17 | 2019-10-31 | Vertex Pharma | Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr |
| EP3277321B1 (en) | 2015-04-01 | 2024-08-14 | AnaptysBio, Inc. | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| DK3358347T3 (da) * | 2015-09-30 | 2020-11-30 | Univ Tohoku | Markør til bestemmelse af diabetisk nefropati |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| FI3478286T3 (fi) | 2016-06-29 | 2024-03-14 | Tesaro Inc | Menetelmiä munasarjasyövän hoitamiseksi |
| CN119606965A (zh) | 2016-07-29 | 2025-03-14 | 詹森药业有限公司 | 治疗前列腺癌的方法 |
| CN107663190B (zh) * | 2016-07-29 | 2020-06-09 | 钟桂发 | 一种尼拉帕尼及其中间体的制备方法以及中间体化合物 |
| CN106432057A (zh) * | 2016-09-17 | 2017-02-22 | 青岛云天生物技术有限公司 | 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法 |
| SG11201903867YA (en) | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| EP3666794A1 (en) | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| JP7118073B2 (ja) | 2017-01-09 | 2022-08-15 | テサロ， インコーポレイテッド | 抗ｔｉｍ－３抗体を用いてがんを処置する方法 |
| EP3565844B8 (en) | 2017-01-09 | 2023-04-12 | Tesaro, Inc. | Methods of treating cancer with anti-pd-1 antibodies |
| BR112019020191A2 (pt) * | 2017-03-27 | 2020-04-22 | Tesaro Inc | formulações de niraparib |
| EA201992177A1 (ru) * | 2017-03-27 | 2020-02-25 | Тесаро, Инк. | Композиции на основе нирапариба |
| WO2018187187A1 (en) * | 2017-04-04 | 2018-10-11 | Combiphos Catalysts, Inc. | Deuterated (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide |
| EA201992430A1 (ru) | 2017-04-13 | 2020-02-28 | Янссен Фармацевтика Нв | Комбинированная терапия рака предстательной железы |
| CN110753684A (zh) | 2017-04-24 | 2020-02-04 | 特沙诺有限公司 | 尼拉帕利的制造方法 |
| SG11201909395TA (en) | 2017-04-27 | 2019-11-28 | Tesaro Inc | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| EP3624850A1 (en) | 2017-05-18 | 2020-03-25 | Tesaro, Inc. | Combination therapies for treating cancer |
| CN108530425A (zh) * | 2017-05-27 | 2018-09-14 | 广州科锐特生物科技有限公司 | 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法 |
| CN109081828B (zh) * | 2017-06-14 | 2021-03-26 | 上海时莱生物技术有限公司 | 聚(adp-核糖)聚合酶抑制剂、制备方法及用途 |
| EP3668857B1 (en) | 2017-08-14 | 2023-07-05 | Teva Pharmaceuticals International GmbH | Processes for the preparation of niraparib and intermediates thereof |
| EP3682236A1 (en) * | 2017-09-13 | 2020-07-22 | B.R.A.H.M.S GmbH | Proadrenomedullin as indicator for renal replacement therapy in critically ill patients |
| EP4027145A1 (en) * | 2017-09-13 | 2022-07-13 | B.R.A.H.M.S GmbH | Pro-adm for therapy monitoring of intensive care unit patients |
| EP3682246A1 (en) * | 2017-09-13 | 2020-07-22 | B.R.A.H.M.S GmbH | Method for guidance of fluid therapy based on proadrenomedullin |
| AU2018341479B2 (en) * | 2017-09-26 | 2022-02-17 | Tesaro, Inc. | Niraparib formulations |
| KR20200086664A (ko) | 2017-09-30 | 2020-07-17 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| MA50618A (fr) * | 2017-10-06 | 2020-08-12 | Tesaro Inc | Polyrhérapies et leurs utilisations |
| CA3087060A1 (en) | 2017-12-27 | 2019-07-04 | Tesaro, Inc. | Methods of treating cancer |
| EP3749352A1 (en) | 2018-02-05 | 2020-12-16 | Tesaro Inc. | Pediatric niraparib formulations and pediatric treatment methods |
| TWI852940B (zh) | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
| CN118994103A (zh) * | 2018-10-03 | 2024-11-22 | 特沙诺有限公司 | 尼拉帕利盐 |
| US20210347758A1 (en) * | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Crystalline Forms of Niraparib Freebase |
| WO2020072860A1 (en) | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Niraparib solid state form |
| EP3966782A2 (en) | 2019-05-06 | 2022-03-16 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
| CN110407704B (zh) * | 2019-08-19 | 2022-05-17 | 常州沃腾化工科技有限公司 | 一种3-甲酰基-2-硝基苯甲酸甲酯的合成方法 |
| CN114391013B (zh) | 2019-09-24 | 2024-01-26 | 上海美悦生物科技发展有限公司 | 一种irak抑制剂及其制备方法和用途 |
| AU2021269115A1 (en) | 2020-05-08 | 2023-01-19 | Janssen Pharmaceutica Nv | Treatment of prostate cancer with a combination of abiraterone acetate and niraparib |
| EP4373491A1 (en) | 2021-07-19 | 2024-05-29 | JANSSEN Pharmaceutica NV | Treatment of metastatic castration-resistant prostate cancer with niraparib |
| MX2024009626A (es) | 2022-02-04 | 2024-08-09 | Janssen Pharmaceutica Nv | Niraparib y acetato de abiraterona mas prednisona para mejorar los resultados clinicos en pacientes con cancer de prostata resistente a la castracion metastasico y alteraciones del hrr. |
| US20250352534A1 (en) | 2022-02-15 | 2025-11-20 | Tesaro, Inc. | Use of Niraparib for the Treatment of Brain Cancer |
| EP4712976A1 (en) | 2023-05-17 | 2026-03-25 | Tesaro, Inc. | Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer |
| WO2025027138A1 (en) | 2023-08-02 | 2025-02-06 | Janssen Pharmaceutica Nv | Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer |
| CN117843713A (zh) * | 2023-12-18 | 2024-04-09 | 上海亲合力生物医药科技股份有限公司 | 基于肿瘤微环境激活的激酶抑制剂、组合物及应用 |
| CN119707921B (zh) * | 2024-12-19 | 2026-03-03 | 四川轻化工大学 | 一种尼拉帕尼的合成方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| AT401651B (de) * | 1994-06-14 | 1996-11-25 | Biochemie Gmbh | 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4- |
| PT841924E (pt) | 1995-08-02 | 2003-02-28 | Univ Newcastle Ventures Ltd | Compostos de benzimidazolo |
| WO1999059973A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
| IL142760A (en) | 1998-10-30 | 2005-12-18 | Lonza Ag | Method for producing 4-Ä(2',5'-diamino-6'- halopyrimidine-4' -yl) aminoÜ-cyclopent -2- enyl-methanols |
| EP1391457B1 (de) | 1998-11-03 | 2013-12-25 | AbbVie Deutschland GmbH & Co KG | Substituierte 2-Phenylbenzimidazole und deren Verwendung als PARP Inhibitoren |
| AU755694B2 (en) | 1998-11-17 | 2002-12-19 | Basf Aktiengesellschaft | 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| USRE39608E1 (en) | 1998-11-27 | 2007-05-01 | Abbott Gmbh & Co. Kg | Substituted benzimidazoles and their use as PARP inhibitors |
| DE19918211A1 (de) * | 1999-04-22 | 2000-10-26 | Basf Ag | Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| WO2001021615A1 (fr) | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Dérivés de benzimidazole |
| US6508365B1 (en) * | 1999-12-28 | 2003-01-21 | Pitney Bowes Inc. | Method of removing mail from a mailstream using an incoming mail sorting apparatus |
| US7041675B2 (en) * | 2000-02-01 | 2006-05-09 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as PARP inhibitors |
| DE10022925A1 (de) * | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
| JPWO2002068407A1 (ja) | 2001-02-28 | 2004-06-24 | 山之内製薬株式会社 | ベンゾイミダゾール化合物 |
| WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| WO2003062234A1 (en) | 2002-01-23 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Quinoxaline compounds |
| US20040034078A1 (en) | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| AU2003252315A1 (en) | 2002-08-09 | 2004-02-25 | Kyorin Pharmaceutical Co., Ltd. | 4-substituted-quinoline-8-carboxylic amide derivatives and pharmacologically acceptable addition salts thereof |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| KR20060037391A (ko) * | 2003-07-21 | 2006-05-03 | 스미스클라인 비참 코포레이션 | (2Ｓ,4Ｓ)-4-플루오로-1-[4-플루오로-베타-(4-플루오로페닐)-Ｌ-페닐알라닐]-2-피롤리딘카르보니트릴 ｐ-톨루엔설폰산염 및 이의 무수 결정 형태 |
| WO2005047290A2 (en) * | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| GB0327740D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compounds |
| US7544707B2 (en) | 2003-12-22 | 2009-06-09 | Eli Lilly And Company | Bicyclic derivatives as PPAR modulators |
| PL1794163T3 (pl) | 2004-09-22 | 2010-06-30 | Pfizer | Sposób wytwarzania inhibitorów poli(adp-rybozo)polimerazy |
| DE602005023333D1 (de) * | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
| JP3701964B1 (ja) * | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| WO2006110683A1 (en) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors |
| EP1895898B1 (en) | 2005-06-29 | 2011-02-16 | Compumedics Limited | Sensor assembly with conductive bridge |
| CA2623822C (en) | 2005-09-29 | 2013-11-12 | Abbott Laboratories | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
| WO2007059230A2 (en) * | 2005-11-15 | 2007-05-24 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| US20090275619A1 (en) | 2006-04-03 | 2009-11-05 | BOUERES Julia | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors |
| US20070259937A1 (en) * | 2006-05-02 | 2007-11-08 | Giranda Vincent L | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| US7892667B2 (en) * | 2006-09-13 | 2011-02-22 | Altek Corporation | Battery security device |
| EA016079B1 (ru) * | 2007-01-10 | 2012-01-30 | Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа | Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp) |
| JP2008228154A (ja) * | 2007-03-15 | 2008-09-25 | Fujitsu Ltd | 表示装置，および遠隔操作装置 |
-
2009
- 2009-01-08 NZ NZ586675A patent/NZ586675A/en unknown
- 2009-01-08 US US12/811,922 patent/US8436185B2/en active Active
- 2009-01-08 KR KR1020107015011A patent/KR101653548B1/ko active Active
- 2009-01-08 MX MX2010006593A patent/MX337421B/es active IP Right Grant
- 2009-01-08 AU AU2009203598A patent/AU2009203598B2/en active Active
- 2009-01-08 CN CN201610345956.4A patent/CN106008460B/zh active Active
- 2009-01-08 BR BRPI0906020-0A patent/BRPI0906020A2/pt not_active Application Discontinuation
- 2009-01-08 JP JP2010541101A patent/JP5989965B2/ja active Active
- 2009-01-08 WO PCT/GB2009/000041 patent/WO2009087381A1/en not_active Ceased
- 2009-01-08 CA CA2711491A patent/CA2711491C/en active Active
- 2009-01-08 EP EP09700579.7A patent/EP2240466B1/en active Active
- 2009-01-08 CN CN2009801018616A patent/CN101932572A/zh active Pending
- 2009-01-08 ES ES09700579.7T patent/ES2548131T3/es active Active
-
2010
- 2010-06-01 ZA ZA2010/03902A patent/ZA201003902B/en unknown
- 2010-06-06 IL IL206201A patent/IL206201A/en active Protection Beyond IP Right Term
-
2018
- 2018-05-14 FR FR18C1020C patent/FR18C1020I2/fr active Active
- 2018-05-15 NL NL300938C patent/NL300938I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2711491A1 (en) | 2009-07-16 |
| NL300938I2 (nl) | 2019-01-08 |
| EP2240466A1 (en) | 2010-10-20 |
| CN101932572A (zh) | 2010-12-29 |
| RU2495035C2 (ru) | 2013-10-10 |
| EP2240466B1 (en) | 2015-07-29 |
| AU2009203598B2 (en) | 2013-09-26 |
| BRPI0906020A2 (pt) | 2015-06-30 |
| JP2011509252A (ja) | 2011-03-24 |
| MX2010006593A (es) | 2010-12-21 |
| AU2009203598A1 (en) | 2009-07-16 |
| ZA201003902B (en) | 2011-02-23 |
| RU2010133241A (ru) | 2012-02-20 |
| IL206201A0 (en) | 2010-12-30 |
| WO2009087381A1 (en) | 2009-07-16 |
| KR101653548B1 (ko) | 2016-09-02 |
| FR18C1020I2 (fr) | 2019-06-07 |
| FR18C1020I1 (enExample) | 2018-07-13 |
| US8436185B2 (en) | 2013-05-07 |
| CN106008460B (zh) | 2022-08-12 |
| JP5989965B2 (ja) | 2016-09-07 |
| CN106008460A (zh) | 2016-10-12 |
| NZ586675A (en) | 2012-04-27 |
| CA2711491C (en) | 2016-03-08 |
| KR20100114021A (ko) | 2010-10-22 |
| IL206201A (en) | 2014-07-31 |
| ES2548131T3 (es) | 2015-10-14 |
| US20100286203A1 (en) | 2010-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009013077A (es) | Derivados dde benzoxazolona. | |
| WO2010108187A3 (en) | Compounds and methods for treating mammalian gastrointestinal microbial infections | |
| PH12013501772A1 (en) | Inhibitors of e1 activating enzyme | |
| MY155719A (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| NZ603525A (en) | Pyrimidine based compound and uses thereof | |
| MX2009013341A (es) | Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina. | |
| MX2009009948A (es) | Derivados de piridazinona utiles como inhibidores de glucano sintasa. | |
| NO20090434L (no) | Heteroarylforbindelser anvendbare som inhibitorer av E1-aktiverende enzymer | |
| GEP20125564B (en) | Pyrimidine derivatives as kinase inhibitors | |
| MX2009012708A (es) | Derivados de piridazinona. | |
| MY163477A (en) | Pyrimidinyl-pyridazinone derivatives | |
| EA201001412A1 (ru) | Ингибиторы киназы pim и способы их применения | |
| MX2010005343A (es) | Compuestos indola 3, 5-sustituidos que tienen actividad inhibidora de la re-absorcion y el reciclo de nos y norepinefrina. | |
| TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
| ATE456565T1 (de) | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren | |
| NZ592925A (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| MY191825A (en) | Therapeutic compounds and compositions | |
| WO2014028931A3 (en) | Compounds and methods for treating mammalian gastrointestinal microbial infections | |
| NZ702050A (en) | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof | |
| WO2010002956A3 (en) | Heterocyclic derivatives as modulators of ion channels | |
| IL205696A0 (en) | Heterocyclic derivatives, compositions comprising the same and uses thereof | |
| EA200901603A1 (ru) | Арил-эфирные производные пиридазинона | |
| ECSP10010411A (es) | INHIBIDORES HETEROCÍCLICOS DE ESTEAROIL-CoA-DESATURASA | |
| BRPI0506802A (pt) | derivados de indol e uso destes como inibidores de quinase em inibidores de ikk2 particulares | |
| IL219644A0 (en) | Kinase inhibitors and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: MERCK SHARP & DOHME LTD. |
|
| HC | Change of company name or juridical status |
Owner name: MERCK SHARP & DOHME LTD. |
|
| FG | Grant or registration |